MedicinePharmacotherapyUrologyBladder ManagementUrodynamicsVoiding DysfunctionBladder ComplianceDetrusor Muscle FunctionIncontinence ManagementUrge Urinary IncontinenceUrinary ContinenceUrinary IncontinenceBladder Capacity DevelopmentBladder Capacity ReductionBladder Capacity RestorationPharmacologic Treatment Of IncontinencePharmacological TherapyPharmacology Of Detrusor ActivityPlacebo Effect In TreatmentUrge Incontinence Management
46 patients suffering from urgency/urge incontinency were treated with Mictonorm and Spasuret in a crossing-over study. In consideration of the placebo effect in this disease both agents were tested versus a non-verum. The application period was 4 weeks and the dosage was 45 mg/d Mictonorm and 300 mg/d Spasuret, respectively. Both with Mictonorm and with Spasuret a significant reduction of micturition frequency and an increase of the compliance could be observed, whereas the placebo was ineffective. A markedly growth of the maximal bladder capacity (16.9%) was obtained only by Mictonorm. Both agents keep likewise to an improvement of the symptoms or urgency/urge incontinency. Side effects could observed in a small size without a breaking-off of the treatment.